Share on LinkedInShare on LinkedIn

VIDEO · 18 NOVEMBER 2026

Biotech IPOs: Going Public And Beyond (Video)

Partners Ross McNaughton and Mike Blankenship explore the critical decisions that shape a biotech IPO through six focused conversations. From understanding what makes biotech valuations...

United StatesFinance and Banking

Conversations on timing, valuation, readiness, and life as a public biotech company.

Going public takes more than strong science. You need the right timing, a credible valuation, and a plan for what comes next.

Join Partners Ross McNaughton and Mike Blankenship for six focused conversations on the decisions that shape a biotech IPO, from readiness and funding to the demands of life as a public company.

Episode 1: Why are biotech IPOs so different?

Biotech investors are funding science, not revenue growth. Discover why clinical milestones, approval prospects, and future commercial potential drive the investment story, and what that means for risk and value.

Episode 2: When is the right time to go public?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from